Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its ...
Yesterday the US Food and Drug Administration (FDA) approved a freeze-dried formulation of Bavarian Nordic's mpox vaccine, ...
This recent safety and effectiveness data regarding mpox vaccination with Jynneos is important and timely given the ongoing ...
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS ...
A new report from GlobalData has raised concerns over the effectiveness of mpox vaccines for people living with HIV. Findings ...
Jynneos was the first smallpox vaccine developed under Project BioShield, a program created by Congress in 2004 to accelerate ...
EUROPEAN shares rebounded on Tuesday from a two-month low touched in the previous session, while the market braced for an ...
3d
Pharmaceutical Technology on MSNFDA approves Bavarian Nordic’s freeze-dried mpox and smallpox vaccineThe formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine ...
The Company has been contracted by the U.S Biomedical Advanced Research and Development Authority (BARDA) to develop and supply a freeze-dried version of JYNNEOS for stockpiling. Manufacturing under ...
The US Food and Drug Administration (FDA) has approved the freeze-dried formulation of Bavarian Nordic’s smallpox and mpox vaccine in a move expected to provide flexibility in stockpiling the jab.
COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results